AbbVie (ABBV) — Upcoming Catalysts
FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for AbbVie, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.
For informational purposes only — not investment advice. Track ABBV live on Mooboard →
This week2
- Oct 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutAflibercept (EYLEA®) · Phase 3 · AMD; nAMDNCT05407636: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD. Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutAGN-151586 · Phase 2 · Forehead LinesNCT07730554: A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants. Primary completion 2026-10 (estimated); status RECRUITING.
31–90 days8
- Nov 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutVenetoclax · Phase 2 · Chronic Lymphocytic Leukemia (CLL)NCT04895436: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL). Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutBudigalimab · Phase 2 · Hepatocellular CarcinomaNCT05822752: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC). Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutABBV-932 · Phase 2 · Generalized Anxiety Disorder (GAD)NCT06846320: Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutMirvetuximab soravtansine · Phase 2 · High Grade Ovarian Cancer; Primary Peritoneal CancerNCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutLutikizumab · Phase 3 · Hidradenitis SuppurativaNCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa. Primary completion 2026-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutABBV-400 · Phase 2 · Unresectable Metastatic Colorectal CancerNCT06107413: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab. Primary completion 2026-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutRanibizumab (LUCENTIS®) · Phase 2 / Phase 3 · AMD; nAMDNCT04704921: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD. Primary completion 2026-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Dec 18, 2026ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutMEDI0618 · Phase 2 · MigraineNCT06602479: A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine. Primary completion 2026-12-18 (estimated); status RECRUITING.
Later15
- Jan 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutPlacebo · Phase 3 · Atopic DermatitisNCT06701331: Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis. Primary completion 2027-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Jan 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutLivmoniplimab · Phase 2 / Phase 3 · Hepatocellular CarcinomaNCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC). Primary completion 2027-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutLutikizumab · Phase 2 · Rheumatoid ArthritisNCT06972446: A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis. Primary completion 2027-02 (estimated); status RECRUITING.
- Feb 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutAzacitidine · Phase 1 / Phase 2 · Acute Myeloid LeukemiaNCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia. Primary completion 2027-02 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutMirvetuximab Soravtansine · Phase 2 · Recurrent Ovarian Cancer; Folate Receptor-Alpha PositiveNCT06365853: A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression. Primary completion 2027-02 (estimated); status ACTIVE_NOT_RECRUITING.
- Feb 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutLutikizumab · Phase 2 · Hidradenitis Suppurativa; Atopic DermatitisNCT06524635: A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab. Primary completion 2027-02 (estimated); status RECRUITING.
- Mar 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutLivmoniplimab · Phase 2 · Urothelial CarcinomaNCT06632951: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC). Primary completion 2027-03 (estimated); status ACTIVE_NOT_RECRUITING.
- Mar 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutABBV-932 · Phase 2 · Bipolar I or II DisorderNCT07220460: Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder. Primary completion 2027-03 (estimated); status ACTIVE_NOT_RECRUITING.
- Mar 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutUpadacitinib · Phase 3 · Systemic Lupus ErythematosusNCT05843643: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus. Primary completion 2027-03 (estimated); status ACTIVE_NOT_RECRUITING.
- Mar 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutRisankizumab SC · Phase 3 · Crohn's DiseaseNCT06063967: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.. Primary completion 2027-03 (estimated); status ACTIVE_NOT_RECRUITING.
- Mar 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutCariprazine · Phase 3 · Depression; Bipolar I DisorderNCT04777357: A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.. Primary completion 2027-03 (estimated); status RECRUITING.
- Apr 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutMirvetuximab soravtansine plus Bevacizumab · Phase 3 · Ovarian Cancer; Peritoneal CancerNCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer. Primary completion 2027-04 (estimated); status ACTIVE_NOT_RECRUITING.
- May 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutUbrogepant · Phase 3 · MigraineNCT05125302: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17). Primary completion 2027-05 (estimated); status RECRUITING.
- May 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutLutikizumab · Phase 2 · Atopic DermatitisNCT06718101: A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis. Primary completion 2027-05 (estimated); status ACTIVE_NOT_RECRUITING.
- Jun 2027ClinicalTrials.gov ↗AbbVie(ABBV)Phase 2/3 readoutUpadacitinib · Phase 3 · Crohn's DiseaseNCT06332534: Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease. Primary completion 2027-06 (estimated); status RECRUITING.
How AbbVie has moved — past-year price reactions
How binary is ABBV? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.
1%
0
26.5%
249
Largest single-day moves
- +6.2%2026-06-22no matched headline
- +5.5%2025-10-01no matched headline
- -5.2%2026-03-18no matched headline
- -4.5%2025-10-31no matched headline
- +4.2%2026-01-07no matched headline
- +4.2%2026-07-16no matched headline
Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.
AbbVie — active clinical pipeline
AbbVie's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.
79 assets140 programsPh1 46Ph2 44Ph3 47· 3 post-marketing (Ph4)
AreasOncologyAutoimmuneImmunologyMetabolicNeuroscienceOphthalmologyRare / GeneticOther
Telisotuzumab AdizutecanOncology
Phase 1
Phase 2
UpadacitinibAutoimmune
risankizumabAutoimmune · IL-12/23
Phase 1
Phase 2
LutikizumabImmunology · IL-1α/1β
Phase 2
Phase 3
EtentamigOncology
Phase 2
ABBV-706Oncology
Phase 1
Phase 2
Phase 3
AtogepantNeuroscience · CGRP
VenetoclaxOncology · BCL-2
Telisotuzumab vedotinOncology · MET ADC
Phase 3
25mg EluxadolineOther
Phase 3
ABBV-1480Oncology
Phase 3
ABBV-RGX-314Ophthalmology
Phase 3
AdalimumabAutoimmune · TNF
Phase 3
Armour ThyroidOther
Phase 3
ElagolixOther · GNRHR
Phase 3
Mirvetuximab soravtansine plus BevacizumabOncology
Phase 3
NOA LIFTOther
Phase 3
PomalidomideOncology · cereblon
Phase 3
Risankizumab IVAutoimmune
Phase 3
Risankizumab SCAutoimmune
Phase 3
Surabgene LomparvovecOphthalmology
Phase 3
Surabgene Lomparvovec (ABBV-RGX-314)Ophthalmology
Upadacitinib (ABT-494)Autoimmune
Phase 3
ABBV-932Neuroscience
Phase 1
Mirvetuximab SoravtansineOncology · FRα ADC
ABBV-142Other
ABBV-383 (Etentamig)Rare / Genetic
ABBV-6628Ophthalmology
Phase 2
AGN-151607-DPOther
Phase 2
AGN-193408 SROphthalmology
Phase 2
AzacitidineOncology · DNA/RNA/DNMT1/DNMT3A
Phase 2
BudigalimabOncology · PD-1
Phase 2
CarboplatinOncology · DNA
Phase 2
DexamethasoneOncology · NR3C1
Phase 2
IcalcaprantNeuroscience
Phase 2
IMGN632Oncology · DNA/CD123
RanibizumabOphthalmology · VEGF
RGX-314Ophthalmology
SurzetoclaxOncology
Phase 2
TNB-383BOncology
Phase 2
ABBV-319Oncology
ABBV-927Oncology · CD40
ABBV-101Oncology
Phase 1
ABBV-1042Other
Phase 1
ABBV-1451Other
Phase 1
ABBV-243Other
Phase 1
ABBV-253Oncology
Phase 1
ABBV-291Oncology
Phase 1
ABBV-313Other
Phase 1
ABBV-438Oncology
Phase 1
ABBV-453Oncology
ABBV-519Autoimmune
Phase 1
ABBV-525Oncology
ABBV-547Other
Phase 1
ABBV-637Oncology
Phase 1
ABBV-701Other
Phase 1
ABBV-711Oncology
Phase 1
ABBV-722Other
Phase 1
ABBV-744Oncology
Phase 1
ABBV-859Other
Phase 1
ABBV-901Oncology
Phase 1
AzirkitugOncology
Phase 1
BretisilocinOther
Phase 1
Etentamig (ABBV-383)Oncology
Phase 1
LenvatinibOncology
Phase 1
ObinutuzumabOncology · CD20
Phase 1
OsimertinibOncology · EGFR
Phase 1
Subcutaneous (SC) EtentamigOncology
Phase 1
Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).
Targets from a ChEMBL (EMBL-EBI) snapshot dated 2026-08-20 · 310/1701 assets resolved when it was built
See the full biopharma catalyst calendar across all covered companies.